 |
|
|
| |
High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Eric Lawitz1, John Vierling2, Abel Murillo3, Marcelo Kugelmas4, Jan Gerstoft5, Peter Winkle 6, Luis Balart7, Peer Christensen8, Reem Ghalib9, Ronald Nahass10, Melissa Shaughnessy11, Xiao Sun11, Peggy Hwang11, Janice Wahl11, Michael Robertson11, Barbara Haber11
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA, 2Baylor College of Medicine, Houston, TX, USA, 3Advanced Medical & Pain Management Research Clinic, Miami, FL, USA, 4South Denver Gastroenterology, Denver, CO, USA, 5Epidemiklinikken, Rigshospitalet, Copenhagen, Denmark, 6Assoc Gastroenterology Medical Group, Anaheim, CA, USA, 7Tulane University Medical Center, New Orleans, LA, USA, 8Dept. Infectious Diseases, Odense University Hospital, Odense, Denmark 9Texas Clinical Research Institute, Arlington, TX USA, 10ID Care, Hillsborough, NJ, USA, 11Merck & Co., Inc., Whitehouse Station, NJ USA
|
| |
|
|
|
|
|
